Regeneron Pharmaceuticals Inc Earnings
The next earnings date for Regeneron Pharmaceuticals Inc has not yet been scheduled.
Analyst Estimates of Regeneron Pharmaceuticals Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Regeneron Pharmaceuticals Inc Earnings: Historical
| 07/30/2026 | Before Market | $12.53 | 56.63% |
| 04/29/2026 | Before Market | $9.47 | 6.40% |
| 01/30/2026 | Before Market | $11.44 | 6.42% |
| 10/28/2025 | Before Market | $11.83 | 22.72% |
| 08/01/2025 | Before Market | $12.89 | 52.73% |
| 04/29/2025 | Before Market | $8.22 | -3.07% |
| 02/04/2025 | Before Market | $12.07 | 7.86% |
| 10/31/2024 | Before Market | $12.46 | 6.50% |
| 08/01/2024 | Before Market | $11.56 | 8.85% |
| 05/02/2024 | Before Market | $9.55 | -5.45% |
More About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
“Regeneron Pharmaceuticals Inc Earnings” Can Refer to the Regeneron Pharmaceuticals Inc Earnings Date
Some people say “Regeneron Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Regeneron Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Regeneron Pharmaceuticals Inc Stock on the Earnings Date
If you own Regeneron Pharmaceuticals Inc stock (REGN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Regeneron Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Regeneron Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Regeneron Pharmaceuticals Inc Options on the Earnings Date
If you own Regeneron Pharmaceuticals Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Regeneron Pharmaceuticals Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Regeneron Pharmaceuticals Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Regeneron Pharmaceuticals Inc. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Regeneron Pharmaceuticals Inc options often go down. This is sometimes referred to as volatility crush.
Learning More Regeneron Pharmaceuticals Inc Earnings
You can contact us any time if you would like to ask questions about Regeneron Pharmaceuticals Inc earnings or anything else related to the stock market.